secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001824293-25-000072
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025
--------------------------------------------------------------------------------

- Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.
- Cash $3.3M at March 31; subsequent $5M public offering; cash runway expected through Q3 2025.
- Phase 2a trial of GRI-0621: 6-week interim data (n=24) expected Q2 2025; topline data Q3 2025.
- Interim 2-week data in first 12 patients showed safety, no hyperlipidemia, and biomarker PRO-C3 suggestive of anti-fibrotic effect.
- Enrollment over two-thirds complete for overall Phase 2a IPF trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/0001824293-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/val-20250515.htm
  HTML page:      https://secwatch.observer/filing/0001824293-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer